Pneumococcal Polysaccharide Serotype 33F

This article summarizes several clinical trials investigating the use of pneumococcal vaccines containing the serotype 33F polysaccharide conjugated to CRM197 protein. These trials aim to evaluate the safety, immunogenicity, and effectiveness of new pneumococcal conjugate vaccines in preventing pneumococcal disease in various populations, including healthy adults, children, and those at increased risk. The studies examine immune responses, compare different vaccine formulations, and assess real-world effectiveness against pneumococcal pneumonia.

What is Pneumococcal Polysaccharide Serotype 33F Conjugate Vaccine?
How Does It Work?
What Diseases Does It Help Prevent?
Who Should Get This Vaccine?
How Is It Administered?
Effectiveness
Safety and Side Effects
Ongoing Research

What is Pneumococcal Polysaccharide Serotype 33F Conjugate Vaccine?

Pneumococcal Polysaccharide Serotype 33F Conjugate Vaccine is a component of newer pneumococcal vaccines designed to protect against infections caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus^[1]. This vaccine is part of a group of vaccines called conjugate vaccines, which are more effective than older polysaccharide vaccines, especially in young children and older adults.

How Does It Work?

The vaccine works by stimulating your immune system to produce antibodies against the outer coating (polysaccharide) of the pneumococcal bacteria, specifically serotype 33F. In this vaccine, the polysaccharide is chemically linked (conjugated) to a carrier protein called CRM197^[1]. This conjugation helps to create a stronger and longer-lasting immune response, particularly in infants and older adults whose immune systems might not respond as well to the polysaccharide alone.

What Diseases Does It Help Prevent?

This vaccine helps prevent diseases caused by the pneumococcal bacteria, including:

Pneumonia: An infection of the lungs
Bacteremia: An infection of the blood
Meningitis: An infection of the lining of the brain and spinal cord
Otitis media: Middle ear infections (particularly in children)

These diseases can be serious and even life-threatening, especially for young children, older adults, and people with weakened immune systems^[2].

Who Should Get This Vaccine?

The Pneumococcal Polysaccharide Serotype 33F Conjugate Vaccine is typically included in newer pneumococcal vaccines that are recommended for:

Infants and young children as part of their routine vaccination schedule
Adults 65 years and older
People between 18 and 64 years old who have certain medical conditions that increase their risk of pneumococcal disease

Specific recommendations may vary depending on the exact vaccine formulation and local health guidelines^[3].

How Is It Administered?

The vaccine is typically given as an intramuscular injection, usually in the upper arm for adults or the thigh for infants. The number of doses and schedule can vary depending on the specific vaccine and the age and health status of the recipient^[4].

Effectiveness

Studies have shown that pneumococcal conjugate vaccines, including those containing the serotype 33F component, are highly effective in preventing invasive pneumococcal disease caused by the serotypes included in the vaccine. The effectiveness can vary depending on the individual’s age and health status, but overall, these vaccines have significantly reduced the incidence of severe pneumococcal infections^[5].

Safety and Side Effects

Pneumococcal conjugate vaccines, including those with the serotype 33F component, are generally considered safe. Common side effects may include:

Pain, redness, or swelling at the injection site
Mild fever
Fatigue
Headache
Muscle or joint pain

Serious side effects are rare but can include severe allergic reactions. As with any vaccine, the benefits of protection against disease are considered to outweigh the risks of side effects for most people^[5].

Ongoing Research

Research is ongoing to further improve pneumococcal vaccines and to study their long-term effectiveness. Current studies are looking at the immune response to these vaccines in different age groups and populations, as well as the potential need for booster doses. Additionally, researchers are investigating the vaccine’s effectiveness against non-invasive pneumococcal diseases and its impact on overall pneumococcal disease rates in communities^[6].

Trial Focus	Key Points
Immune Response Study	– Evaluates timing of peak immune responses in lymph nodes – Uses fine needle aspiration to study B and T cell responses – Compares primary vaccination to booster doses
Co-administration Study	– Tests pneumococcal vaccine with RSV vaccine in older adults – Assesses safety and non-inferiority of immune responses – Examines effects on each vaccine when given together
High-Risk Adult Study	– Targets adults 18-64 with increased pneumococcal disease risk – Compares new 21-valent vaccine to current 15-valent + 23-valent regimen – Measures antibody responses and safety
Older Adult Effectiveness Study	– Large study in adults 65+ to evaluate real-world effectiveness – Uses test-negative design to assess protection against pneumonia – Examines effectiveness by age, health conditions, and prior vaccinations
Pediatric High-Risk Study	– Focuses on children/adolescents with chronic health conditions – Compares new 21-valent vaccine to 23-valent polysaccharide vaccine – Evaluates safety and immune responses in this vulnerable group

Trial Focus

Key Points

Immune Response Study

– Evaluates timing of peak immune responses in lymph nodes – Uses fine needle aspiration to study B and T cell responses – Compares primary vaccination to booster doses

Co-administration Study

– Tests pneumococcal vaccine with RSV vaccine in older adults – Assesses safety and non-inferiority of immune responses – Examines effects on each vaccine when given together

High-Risk Adult Study

– Targets adults 18-64 with increased pneumococcal disease risk – Compares new 21-valent vaccine to current 15-valent + 23-valent regimen – Measures antibody responses and safety

Older Adult Effectiveness Study

– Large study in adults 65+ to evaluate real-world effectiveness – Uses test-negative design to assess protection against pneumonia – Examines effectiveness by age, health conditions, and prior vaccinations

Pediatric High-Risk Study

– Focuses on children/adolescents with chronic health conditions – Compares new 21-valent vaccine to 23-valent polysaccharide vaccine – Evaluates safety and immune responses in this vulnerable group

Ongoing Clinical Trials on Pneumococcal Polysaccharide Serotype 33F

Glossary

Pneumococcal disease: Infections caused by the bacteria Streptococcus pneumoniae, which can lead to pneumonia, meningitis, and bloodstream infections.
Conjugate vaccine: A type of vaccine where a weak antigen is attached to a strong antigen to improve the immune response, especially in young children.
Serotype: A distinct variation within a species of bacteria, in this case referring to different strains of Streptococcus pneumoniae.
CRM197: A non-toxic mutant of diphtheria toxin used as a carrier protein in conjugate vaccines to enhance the immune response.
Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
Opsonophagocytic activity (OPA): A measure of antibody function that indicates how well antibodies help immune cells engulf and destroy bacteria.
Geometric mean titer (GMT): A way of averaging antibody levels in a group of people that accounts for wide ranges in individual values.
Community-acquired pneumonia (CAP): Pneumonia that develops outside of hospitals or healthcare facilities, often caused by common bacteria like pneumococcus.
Vaccine effectiveness (VE): A measure of how well a vaccine prevents disease in real-world conditions, usually expressed as a percentage.
Pneumococcal conjugate vaccine (PCV): A vaccine that protects against multiple strains of pneumococcus by linking bacterial sugars to a protein to improve immune response.

References

http://clinicaltrials.eu/trial-id/2022-501519-15-00
http://clinicaltrials.eu/trial-id/2022-501988-40-00
http://clinicaltrials.eu/trial-id/2022-502791-22-01
http://clinicaltrials.eu/trial-id/2022-503144-40-00
http://clinicaltrials.eu/trial-id/2023-506236-32-00
http://clinicaltrials.eu/trial-id/2023-507293-40-00

#1 Clinical Trials Search in Europe